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Abstract Currently, there are no sensitive diagnostic
tests that could allow early detection of lung cancer.
Among some cancer patients, epigenetic changes in the
nature of methylation of different gene promoter regions
are observed, which affect expression of suppressor genes
such as septin 9 (SEPT9). Due to the ability of detecting
these changes in free circulating DNA in peripheral blood,
such genes may become ideal markers in early and non-
invasive diagnostics of cancer. Methylation of SEPT9
promoter region in plasma DNA is observed frequently in
colorectal cancer patients. The aim of the study was to
define the frequency of SEPT9 promoter methylation in
lung cancer patients and evaluation of usefulness of this
marker in early diagnostic of lung cancer. Plasma samples
were obtained from 70 untreated patients with different
lung cancer pathological diagnosis and disease stage and
from 100 healthy individuals. DNA was isolated from
peripheral blood plasma and was then subjected to bisulf-
itation, purification and elution using Abbott mSEPT9
Detection Kit. Methylation level was assessed by real-time
PCR with the use of specific SEPT9 promoter methylation
probe. Each sample was assayed in the presence of positive
and negative control. SEPT9 promoter methylation was
detected in 31 (44.3 % of the whole studied group) of lung
cancer patients finding the result positive when methylation
was detected in 1 out of 3 repetitions of each test sample
determinations. The marker was present in patients with
different pathological diagnosis and disease stage. Analysis
of SEPT9 promoter region methylation may be useful in
early diagnosis of lung cancer.
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Introduction
Lung cancer is the most frequent malignancy in the world
and is a major cause of cancer deaths in developed coun-
tries. Unfortunately, in many cases, the disease is diag-
nosed too late, in an inoperable stage III or IV, and the
5-year survival rate usually does not exceed 10 % [1, 3].
Despite developments in understanding lung cancer biol-
ogy and the advances of molecular biology techniques,
which allow to use personalized molecularly targeted
treatment based on predictive markers (mutations, gene
rearrangements), there is still lack of sensitive and specific
tests to detect early neoplastic lesions. Currently, in the
world, there are no set criteria of screening for the early
detection of lung cancer, although attempts are being made
to use computed tomography (CT) in the group of intensive
smokers. Although CT and positron emission tomography
(PET) allow to visualize early neoplastic changes in lungs,
it is an expensive examination and the number of patients
in the program is small. In addition, such examinations
may pose diagnostic problems, providing false-positive
results and revealing high percentage of nodules of inde-
terminate and often non-benign nature [1–3]. The greatest
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hopes for the early diagnosis of lung cancer are associated
with the search for suitably sensitive and specific biological
markers detectable by molecular biology techniques in
peripheral blood.
In some cancer patients, epigenetic changes in the nature
of methylation of different gene promoter regions is
observed, which affects their expression [4]. Such phe-
nomena may be detected in free circulating DNA (fc-DNA)
of peripheral blood. One of the recently discovered epi-
genetic changes is methylation of septin 9 (SEPT9) gene. It
is a suppressor gene whose expression disorders are prob-
ably one of the causes of few cancer types development.
Decrease in expression of this gene is most often connected
with methylation of its promoter region, which induces
cancer cell proliferation and migration. It results in an
acceleration of tumor growth and facilitates creation of
distant metastases. Decreased expression of SEPT9 gene
was observed in colon, prostate and breast cancers. Prob-
ably, the decreased expression of SEPT9 is also found in
tumors of ovary, pancreas, lung, kidney, liver, thyroid, and
esophagus [5]. Increased promoter methylation of SEPT9
in fc-DNA of peripheral blood plasma appears to be par-
ticularly common in colorectal cancer patients, and the
assessment of methylation in this type of malignancy is
nowadays possible with commercial CE-IVD (in vitro
diagnostic) test. However, there are no reports about the
frequency of this phenomenon in lung cancer patients.
The aim of the study was to assess the frequency of
SEPT9 promoter methylation in patients with various
pathological types and stages of lung cancer, as well as a
pilot evaluation of usefulness of this marker in early
diagnostic of the disease.
Materials and methods
Evaluation of SEPT9 promoter methylation in fc-DNA was
carried out in 70 lung cancer patients (45 men and 25
women, median age 65 years) and 100 healthy individuals
(62 men and 38 women, median age 58 years) of Cauca-
sian origin. Control group and examined group were mat-
ched in term of gender, age and smoking status. Based on
pathologic diagnosis, small cell lung cancer (SCLC) was
diagnosed in 23 patients (33 % of the studied group) and
non-small cell lung cancer (NSCLC) was diagnosed in 47
patients (67 % of the studied group). None of the patients
had radical surgery nor chemo- or radiotherapy. Detailed
characteristic of patients is shown in Table 1.
DNA was isolated from peripheral blood serum samples.
For this purpose, from each patient, 10 ml of blood have
been collected into tubes covered with EDTA-K2. The
samples were then immediately centrifuged at 1,4009g for
12 min to separate plasma from cellular components of
blood. In order to remove impurities which may compromise
the quality of the plasma, it was centrifuged again under the
same conditions and transferred to clean tubes. The mini-
mum volume of plasma necessary for further studies was
4 ml. Such prepared samples have been frozen in -80 C
until the time of analysis. For further analysis and to detect
methylated SEPT9 in each examined sample, we used
Abbott mSEPT9 detection Kit (Abbott Molecular, USA).
To capture DNA from the studied samples, an Abbott
mSample Preparation System DNA kit (CE-IVD), which is
based on magnetic microparticles, was used. In the first
stage, DNA is captured and purified in magnetic field. The
nucleic acid bound to microparticles is then eluted. Non-
methylated cytosine residues are converted into uracil
under the influence of disodium bisulfite. 5-methylcytosine
residues remain unchanged. Bisulfite DNA modification is
carried out with Abbott Bisulfite Modification Kit (CE-
IVD) in T personal thermocycler (Biometra, Germany).
DNA is then once again isolated and purified with Abbott
mSample Preparation System DNA kit and prepared for
real-time PCR.
Real-time PCR was carried out on Abbott m2000rt
instrument (CE-IVD). Every sample was examined in the
presence of positive control, which was human plasma with
addition of DNA with methylated SEPT9 promoter (cancer
cell line) and negative control (DNA with beta-actin
sequences). Amplification was observed only for methyl-
ated SEPT9 gene fragments, which were detected with
probes specific to SEPT9 promoter regions containing
5-methylcytosine. Beta-actin amplicons were created with
the use of primers complementary to beta-actin sequence
and were also detected with specific probes from Abbott
(CE-IVD). Three real-time PCRs were carried out for each
studied sample.
To evaluate the sensitivity and specificity of the SEPT9
test, the following formulas have been used:
Sensitivity ¼ TP=TP þ FN
Specificity ¼ TN=FP þ TN
PPV ¼ TP=TP þ FP
NPV ¼ TN=TN þ FN
TP—True-Positive results, FN—False-Negative results,
FP—False-Positive result, TN—True-Negative results,
PPV—Positive Predictive Value, NPV—Negative Predic-
tive Value.
Additionally in our study, we estimated concentration of
free circulating DNA in plasma of lung cancer patients and
in healthy individuals group. Concentration of plasma
DNA was measured using BioPhotometer plus spectro-
photometer (Eppendorf, Germany). The data are presented
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as the mean and median ± standard deviation. Mann–
Whitney U test was used to show statistical significance of
differences between studied groups. Chi-square test was
used to compare the quantity of patients with different
status of SEPT9 methylation. A level of p \ 0.05 was
assigned significant.
Results
The results of SEPT9 promoter methylation analysis had a
qualitative character (positive or negative) due to the fact
that the test has CE-IVD certificate. Detection of beta-actin
DNA amplification (negative control) allowed to verify an
endogenous sample in respect to properly conducted DNA
isolation, modification with bisulfite and real-time PCR
parameters. For each examined sample (lung cancer
patients and healthy individuals), beta-actin amplification
was obtained.
The examined sample was considered positive when a
negative control probe signal was valid, and a positive
signal from specific probe for methylated SEPT9 promoter
was detected (presence of amplification product of
methylated SEPT9 promoter region) in one out of three
repeats of the same sample. Positive sample result of
cancer patient was showed on Fig. 1. The sample was
considered negative when, in every repetition of the sam-
ple, a beta-actin signal was valid, and no signal for meth-
ylated SEPT9 promoter was detected (Fig. 2).
The presence of methylated SEPT9 promoter region
amplification was observed in 31 (44.3 % of the studied
group) lung cancer patients (53 % of the NSCLC patients
and 26 % of the SCLC patients), in a similar proportion in
both genders. We detected product of amplification in real-
time PCR assay in 10 patients (14.3 %) in 1 out of 3 rep-
licates of the sample and in 8 patients (11.3 %) in 2 out of 3
replicates. However, in 16 positive patients (26 %),
methylated SEPT9 was detected in all replicates of exam-
ined samples (3 out of 3). In 4 healthy individuals (4 %),
SEPT9 methylation was detected in 1 out of 3 replicates of
examined samples.
In 10 lung cancer patients and 4 healthy individuals,
among whom SEPT9 methylation have been detected in 1
out of 3 replicates, the determination was repeated in order
to reject false-positive results. Methylation was detected in
7 NSCLC patients (10 %) in 1 out of 3 replicates and in 2
Table 1 Frequency of SEPT9 promoter methylation in patients with different pathological diagnosis and different disease stage
mS9 (-) negative (0/3) mS9 (?) positive
All mS9 (?) 1/3 2/3 3/3
Median age ± SD (years) 65 ± 9 64 ± 7 64 ± 10 67 ± 7 60 ± 5
All patients (n = 70) 39 (56 %) 31 (44 %) 7 (10 %) 8 (11 %) 16 (23 %)
Sex
Women (n = 25; 36 %) 15 (60 %) 10 (40 %) 4 (16 %) – 6 (24 %)
Men (n = 45; 64 %) 24 (53 %) 21 (47 %) 3 (9 %) 8 (18 %) 10 (22 %)
Pathological diagnosis
NSCL patients (n = 47; 67 %) 22 (47 %) 25 (53 %) 3 (6 %) 7 (15 %) 15 (32 %)
SCLC patients (n = 23; 33 %) 17 (74 %) 6 (26 %) 4 (17 %) 1 (4.5 %) 1 (4.5 %)
Adenocarcinoma (n = 20; 29 %) 9 (45 %) 11 (55 %) 3 (15 %) 1 (5 %) 7 (35 %)
Squamous cell carcinoma (n = 20; 29 %) 8 (40 %) 12 (60 %) 2 (10 %) 3 (15 %) 7 (35 %)
Large cell carcinoma (n = 5; 7 %) 4 (80 %) 1 (20 %) – – 1 (20 %)
NSCLC NOS (n = 2; 2 %) 1 (50 %) 1 (50 %) – 1 (50 %) –
Disease stage of all patients
Early stages IIA-IIIA (n = 23; 33 %) 12 (52 %) 11 (48 %) 3 (13 %) 3 (13 %) 5 (22 %)
Advanced stages IIIB-IV (n = 47; 67 %) 27 (57 %) 20 (43 %) 5 (11 %) 3 (6 %) 12 (26 %)
Disease stage of NSCLC patients
IIA (n = 4; 9 %) 2 (50 %) 2 (50 %) 1 (25 %) 1 (25 %) –
IIB (n = 3; 6 %) 1 (33 %) 2 (67 %) – 1 (33.5 %) 1 (33.5 %)
IIIA (n = 10; 21 %) 4 (40 %) 6 (60 %) 1 (10 %) 1 (10 %) 4 (40 %)
IIIB (n = 13; 28 %) 7 (54 %) 6 (46 %) 1 (7.5 %) 1 (7.5 %) 4 (31 %)
IV (n = 17; 36 %) 8 (47 %) 9 (53 %) 2 (12 %) 1 (6 %) 6 (35 %)
Operable tumor IIA-IIIA (n = 17; 36 %) 7 (41 %) 10 (59 %) 2 (15 %) 3 (18 %) 5 (29 %)
Inoperable tumor IIIB-IV (n = 30; 64 %) 15 (50 %) 15 (50 %) 3 (10 %) 2 (7 %) 10 (33 %)
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patients in 2 out of 3 replicates. One NSCLC patient and all
healthy individuals were found to be negative, as in repe-
tition of the determination, no PCR products have been
found in any of 3 replicates (false-positive results). Fur-
thermore, among all healthy individuals, clinical tests did
not confirm any malignancies.
Based on these results, specificity, sensitivity, PPV and
NPV were determined. Sensitivity was 44.3 %, specificity
was 92.3 %, PPV—91.2 % and NPV—71.1 %. In addition,
sensitivity of SEPT9 methylation determination method
was estimated. For this purpose, methylation was deter-
mined in control DNA with methylated promoter region
and excluded SEPT9 methylation that was diluted 2, 5, 10,
20 and 100-fold. In all dilutions, PCR product was detec-
ted, wherein number of cycles after which amplification
was observed depended on dilution of control DNA
(Figs. 3, 4).
The genetic marker was present in patients with differ-
ent pathological diagnosis and in different disease stage,
also in early IIA and IIB stages. Positive result of the
SEPT9 methylation was observed more frequently in
squamous cell carcinoma (60 %) than in SCLC patients
(26 %) and significantly more frequently in NSCL than
SCLC patients (p = 0.032). Using chi-square test, the
differences between numbers of patients with various status
of mS9 were not shown. However, it is worth mentioning
that the determination of SEPT9 promoter methylation
frequency in subgroups with different pathological diag-
nosis is unreliable because of its low number (Table 1).
The values of plasma DNA concentration ranged from
2.5 up to 31.9 ng/ll (Mean 8.56 ng/ll) in non-treated lung
cancer patients and from 0.1 up to 17.9 ng/ll (Mean
3.92 ng/ll) in healthy individuals group. Lung cancer
patients showed significantly higher concentration of free
circulating DNA (Median 4.56 ng/ll) than healthy group
(Median 3.19 ng/ll, p = 0.0006) (Fig. 5).
Discussion
Currently, lung cancer is mostly detected in advanced stage
which excludes surgery and thus full recovery. The reason for
such phenomenon is an insidious development of the disease,
without characteristic symptoms, and its underestimation by
Fig. 1 The representative
positive result of septin 9
methylation examination
Fig. 2 The representative
negative result of septin 9
methylation examination
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patients. Patients’ fear of cancer and lack of disease suspicion
by first contact physicians, despite first symptoms, have also
significant role in late diagnosis. Therefore, it is crucial to
develop easy to access, simple in execution, and fast and
sensitive molecular biology techniques, which would allow
early lung cancer diagnosis. Preventive use of CT or PET-CT
dose not meet these criteria (especially in the matter of
availability), and regular chest X-rays have too low sensi-
tivity. Moreover, molecular test may be useful in whole
population screening, and their results could qualify selected
patients to more sensitive imaging examinations. Doing so
would increase effectiveness of prophylactics and would
rationalize its costs [1–3].
Biochemical cancer markers such as carcino-embryonic
antigen (CEA) are not specific and have low sensitivity in
early detection of lung malignancies; hence, they have only
limited usefulness in monitoring and evaluation of the
disease after performing surgery or chemotherapy. Due to
the ability of detection of epigenetic changes in fc-DNA in
Fig. 3 Amplification curves for
control DNA with septin 9
methylation diluted with
unmethylated DNA: 1-undiluted
DNA, 2-control DNA diluted
twofold, 3-control DNA diluted
fivefold
Fig. 4 Amplification curves for
control DNA with septin 9
methylation diluted with
unmethylated DNA: 1-control
DNA diluted 10-fold, 2-control
DNA diluted 20-fold, 3-control
DNA diluted 100-fold
Fig. 5 Differences in fc-DNA concentration between lung cancer
patients and healthy donors
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peripheral blood, molecular markers appear to be ideal
candidates for early and noninvasive diagnostics of cancer.
Increased number of methylated SEPT9 promoter region
DNA sequences was observed in colorectal and rectal
cancer patients in comparison with healthy individuals
(among whom methylation level was below the threshold
of sensitivity of molecular methods). Such a phenomenon
was used in detection of colorectal cancer.
Usefulness of SEPT9 promoter methylation examination
was evaluated in a prospective clinical trial PRESEPT. It
concerned early screening of colorectal cancer. Almost
8,000 individuals (over 50 years of age), without disease
symptoms, with indication for colonoscopy, were qualified.
SEPT9 gene promoter methylation in fc-DNA from venous
peripheral blood was found in 67 % of patients with con-
firmed (by colonoscopy) colorectal cancer [6]. Similar
results were obtained by Gru¨tzmann et al. [7] who detected
SEPT9 promoter methylation in peripheral blood in 73 of
126 colorectal cancer patients (58 % of the studied group)
in the first test study. Sensitivity of the used test depended
on disease stage. Positive result was obtained in 50 % of
patients in early stage of disease and in almost 100 % of
patients in advanced stage of colorectal cancer.
Studying promoter methylation of SEPT9 gene in
peripheral blood plasma is a multi-stage process, involving
DNA isolation, purifying and elution of the isolated nucleic
acid and its modification with bisulfite, and in the end real-
time PCR. In order to improve sensitivity and specificity, a
validation of SEPT9 promoter methylation detection
method and optimization of its each stage were proposed.
Some elements, such as application of an internal control
and successive dilution of the sample prior to the assay,
have been added. These changes contributed to raise
detection of colorectal cancer. Inclusion of an additional
measurement replicate increased the sensitivity of the assay
(second test study), Gru¨tzman et al. [7] detected methylated
SEPT9 promoter in plasma of 90 out of 125 patients with
colorectal cancer (72 %). The same result was obtained by
deVos et al. [8] who detected methylation in 65 out of 90
colorectal cancer patients (72 %). In current studies by
Warren et al. and To´th et al., molecular testing confirmed
90 and 95.6 % cases of colorectal cancer in patients with
the disease confirmed with other methods. Unfortunately,
the sensitivity of the molecular method in patients with
stage I colorectal cancer is still low and does not exceed
56 % [5, 8]. Currently, the subject of research is the ability
to detect SEPT9 promoter methylation in other types of
cancer.
Hypermethylation of SEPT9 gene promoter was
observed in head and neck, ovary and breast cancer.
Although the studies were carried on tissues and cell lines,
they cannot be directly applied to the results obtained in
plasma. Furthermore, methylation may concern regions of
SEPT9 gene promoter other than in colorectal cancer [8].
There is also lack of reports on the evaluation of gene
promoter methylation of SEPT9 in patients with lung
cancer. In only one study by Gru¨tzman et al., SEPT9 pro-
moter methylation was evaluated in plasma of patients with
different cancer types, obtaining positive results in 11.5 %
of the studied group. In this non-selected group, also 13
patients with lung cancer have been evaluated, without
taking into account clinical data and pathological diagno-
sis, with positive result in four cases (31 % of lung cancer
patients) [7].
Our results suggest usefulness of detecting epigenetic
changes such as SEPT9 promoter methylation in fc-DNA in
early and noninvasive diagnosis and prevention of lung
cancer. This report is one of the first in the world that
concerns this problem.
It is probable that in lung cancer, similar to colorectal
cancer, methylation level of SEPT9 promoter depends on
the stage of the disease [6–9], although in this study,
methylation was detected in stage II as well as in stage III
and IV. It is worth remembering that the studied group was
small, and there were no patients included in stage I of the
disease. However, a possibility to detect SEPT9 methyla-
tion may depend on the aggressiveness of lung cancer
course. There are no reports on methylation of SEPT9 and
its promoter in different pathologic types of lung cancer.
Expression of SEPT9 gene and the level of its promoter
methylation may be different in small cell lung cancer and
in non-small cell lung cancer, and between each subtypes.
Therefore, assessment of gene promoter methylation of
SEPT9 may prove to be particularly useful in the detection
of specific type or subtype of lung cancer and may be
characterized with different sensitivity and specificity for
each of the subtypes; although based on results from this
study, it appears that positive result may be possible to
achieve in every type of cancer.
Our results are similar to the first reported studies on
SEPT9 promoter methylation in colorectal cancer patients.
It appears that also in this case, validation and optimization
of the detection method may be the key to increase number
of detected lung cancer cases, and the assessment of
methylation may be a useful test in detection, monitoring
and evaluation of disease and its stage, which will certainly
be proven in studies carried out on larger groups of patients
with colorectal cancer.
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